Sign in Subscribe

braf

A collection of 83 issues

ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC

Skip to content The CRC Digest ▸ TREATMENT ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge

Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.

CRC Research Update — September 04, 2026

Today's colorectal cancer research highlights

CRC Research Update — September 03, 2026

Today's colorectal cancer research highlights

Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC

Skip to content The CRC Digest ▸ TREATMENT Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC A population-based multicenter study examined real-world outcomes of the targeted therapy combination encorafenib plus panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and

Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google

CRC Research Update — September 01, 2026

Today's colorectal cancer research highlights

Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era

Skip to content The CRC Digest Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era A narrative review evaluates clinical integration of BRAF-targeted therapy combined with EGFR inhibition, addressing first-line treatment, MMR/MSI status, patient fitness, and sequencing strategies. (J Gastrointest Cancer) This content is informational only and

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

CRC Research Update — August 31, 2026

Today's colorectal cancer research highlights